Masimo Awarded $634M In Apple Patient Monitoring Patent Fight
A California jury found in favor of device firm Masimo in a long-running legal battle against the tech giant. Apple has already announced plans to appeal.
Medtech Insight - November 18, 2025

Digital Health Roundup: BCIs Surge Ahead, Oura Eyes BP Clearance, AI Faces New Scrutiny
Brain-computer interfaces advance toward trials and commercialization, Oura pushes for FDA-cleared blood pressure monitoring, and regulators weigh AI’s expanding role in mental health and diagnostics amid rising safety concerns.
Medtech Insight - November 18, 2025

Vanda Moves Drug For GLP-1 Nausea And Vomiting Into Phase III
The company announced positive Phase II results for tradipitant among patients taking Wegovy, enabling them to move more quickly to a therapeutic dose, when patients normally need to titrate.
Scrip - November 18, 2025

Finance Watch: Solve And Artios Mega-Rounds Show Oncology Still Top Of Mind For VC Investors
Private Company Edition: Solve Therapeutics raised $120m in new funding for its Phase I ADC programs and CloakLink linker platform, while Artios will use its $115m series D cash to fund Phase II trials for its drugs targeting the DNA damage response in cancer, plus other recent VC financings.
Scrip - November 18, 2025

Merck’s Winrevair Poised For A CADENCE Of Growth
A Phase II trial testing Winrevair in patients with a type of hypertension caused by heart failure met the primary endpoint and could represent a big growth opportunity.
Scrip - November 18, 2025

Early Success In Roche’s lidERA Adjuvant Study Builds Giredestrant’s Profile
The data show promise for the investigational SERD as an adjuvant monotherapy, bringing it earlier in the treatment arc for ER-positive/HER2-negative early-stage breast cancer. The next major step for the product is preservERA.
Scrip - November 18, 2025

People On The Move: Appointments At Haleon, Bayer, Boots
A round-up of the latest European people news: Haleon elects board chair; Bayer names group CFO; Boots adds customer & marketing director.
HBW Insight - November 18, 2025

Long-Term Benefits Advance Santhera’s Amgree As DMD Gold Standard Steroid
Five-year Agamree data shows the novel steroid is a safer and equally effective treatment to standard of care deflazacort or prednisone, the Swiss biotech argues.
Scrip - November 18, 2025

Teva Mulls Accelerated Olanzapine Filing Amid Crowded Late-Stage Pipeline
Teva is continuing to decide whether to speed up the FDA review time for its proposed long-acting olanzapine injectable, though the company has numerous options for deploying its priority review voucher across a busy late-stage pipeline.
Generics Bulletin - November 18, 2025

Stock Watch: Addressing Pfizer’s Pandemic Revenue Replacement
As the tide keeps receding on Pfizer’s pandemic product revenues, their replacement was to come from acquisitions. Seagen and Metsera have shown that execution and overpaying are key risks.
Scrip - November 18, 2025

‘We Have Been Forward Looking’: Biocon Biologics On Not Following The Keytruda Biosimilar Hype
Biocon’s biosimilar and generic businesses both delivered double-digit revenue increases, with non-US markets increasingly playing a more important role in the growth strategy.
Generics Bulletin - November 18, 2025

Xbrane Unlocks Funds After Kicking Off Opdivo Biosimilar Trial
Xbrane Biopharma has unlocked some much-needed cash after passing the milestone of kicking off a trial for its Intas-partnered Xdivane (nivolumab) biosimilar rival to Opdivo.
Generics Bulletin - November 18, 2025

Viatris Wins EU Nod For Teduglutide Generic
Viatris has garnered a first positive opinion from the EMA’s CHMP for a teduglutide generic rival to Revestive. At its November meeting the CHMP also endorsed further denosumab and insulin glargine biosimilars, while an insulin aspart filing was withdrawn.
Generics Bulletin - November 18, 2025

Over The Counter Special: Unlocking Switch-Driven Growth, With PAGB’s Michelle Riddalls
Self-Care Week Special: HBW Insight catches up with PAGB CEO Michelle Riddalls OBE to talk about what the association is doing to promote Rx-to-OTC switch in the UK.
HBW Insight - November 18, 2025

J&J Sets Sights On Robust Japan Growth While Tightening Focus
Setting its focus on oncology, immunology and rare diseases, the firm anticipates double-digit growth for 2030.
Scrip - November 18, 2025

US Tariffs: Major Korean Biopharma Firms Ready Different Strategic Responses
Korean biopharma firms are bracing for the impending US tariffs on pharmaceuticals and taking different approaches to tackle the situation.
Scrip - November 18, 2025

Get To Know: Responsibility For Quality Compelled Designs For Health To Make Its Own Supplements
After using supplements from third-party providers for personalized nutrition programs it offered to patients at wellness clinics it operated, Designs for Health has shifted to focus entirely on providing supplements to healthcare practitioners.
HBW Insight - November 18, 2025

Congress’ OMUFA Reauthorization A Win For Sunscreen Non-Animal Testing, Innovation – Industry
Congress’ reauthorization of OMUFA for five years includes measures that promote non-animal testing for sunscreen, a broadening of the evidence that can be used to support safety and additional funding for MoCRA.
HBW Insight - November 18, 2025